Program
lazertinib
Also written as “Lazertinib”, “Lazertinib 240 mg/160 mg” and “YH25448”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Osteoarthritis, Knee, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 125 open or running | phase 3since Jul 23, 2020 | Aug 21, 2019 | Feb 12, 2027phase 1 · NCT04077463 |
| Yuhan | 40 open or running | phase 3since Jan 14, 2020 | Jan 26, 2017 | none ahead |
| Abion | 11 open or running | phase 2since Sep 4, 2022 | Sep 4, 2022 | Feb 2029phase 2 · NCT05541822 |
| BUZZZ Pharmaceuticals | 10 open or running | phase 2since Jul 22, 2021 | Jul 22, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jan 26, 2017.
- Aug 30, 2019Phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463 · 701 enrolled · United States, China, France and more
- Jan 14, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungYuhan · NCT04248829 · 393 enrolled · Australia, Greece, Hungary and more
- May 28, 20202 phase 1 studies in HealthyJohnson & Johnson · NCT04410094, NCT04410081
- Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
- Jul 22, 2021BUZZZ Pharmaceuticals's first study: phase 2 study in Osteoarthritis, KneeNew to BUZZZ PharmaceuticalsBUZZZ Pharmaceuticals · NCT05007808 · 210 enrolled · Canada
- Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
- Sep 17, 2021Phase 1 study in HealthyJohnson & Johnson · NCT05076877 · 20 enrolled · United States
- Nov 2, 2021Phase 1 study in Hepatic ImpairmentJohnson & Johnson · NCT05112952 · 16 enrolled · Germany
- Dec 6, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungYuhan · NCT05162274 · 38 enrolled · Korea, Republic of
- Sep 4, 2022Abion's first study: phase 2 study in Advanced Solid TumorsNew to AbionAbion · NCT05541822 · 178 planned · United States, Korea, Republic of, Taiwan
- Feb 15, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05742594 · 64 enrolled · United States
- Jun 1, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05896683 · 72 enrolled · Belgium
- Oct 30, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667076 · 480 planned · United States, Belgium, Finland and more
- May 8, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT07586202 · 68 planned · United States, Canada, China and more
Ahead
- Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04077463
- Mar 2, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT07586202
- Feb 2029Primary completion: phase 2 study in Advanced Solid TumorsAbion · NCT05541822
- May 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667076
TargetBeta
“An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07586202Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more | 2 | Recruiting | Johnson & Johnson | Mar 2, 2028 | 68 |
| NCT06667076Carcinoma, Non-Small-Cell Lung · United States, Belgium, Finland and more | 2 | Recruiting | Johnson & Johnson | May 23, 2029 | 480 |
| NCT05896683Healthy · Belgium | 1 | Completed | Johnson & Johnson | Sep 1, 2023 | 72 |
| NCT05742594Healthy · United States | 1 | Completed | Johnson & Johnson | Mar 31, 2023 | 64 |
| NCT05541822Advanced Solid Tumors · United States, Korea, Republic of, Taiwan | 2 | Recruiting | Abion | Feb 2029 | 178 |
| NCT05162274Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 1 | Completed | Yuhan | Jan 14, 2022 | 38 |
| NCT05112952Hepatic Impairment · Germany | 1 | Completed | Johnson & Johnson | Jul 11, 2022 | 16 |
| NCT05076877Healthy · United States | 1 | Completed | Johnson & Johnson | Feb 10, 2022 | 20 |
| NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Jul 10, 2023 | 776 |
| NCT05007808Osteoarthritis, Knee · Canada | 2 | Completed | BUZZZ Pharmaceuticals | Jan 4, 2023 | 210 |
| NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Aug 11, 2023 | 1,074 |
| NCT04410094Healthy · United States | 1 | Completed | Johnson & Johnson | Dec 30, 2020 | 32 |
| NCT04410081Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Mar 2, 2021 | 8 |
| NCT04248829Carcinoma, Non-Small-Cell Lung · Australia, Greece, Hungary and more | 3 | Completed | Yuhan | Jul 29, 2022 | 393 |
| NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 1 | Active, not recruiting | Johnson & Johnson | Feb 12, 2027 | 701 |
| NCT04075396Carcinoma, Non-Small-Cell Lung · United States, Spain, United Kingdom | 2 | Completed | Johnson & Johnson | Jan 8, 2021 | 29 |
| NCT03556436Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 1 | Completed | Yuhan | Dec 30, 2018 | 24 |
| NCT03046992Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 2 | Completed | Yuhan | Jan 8, 2021 | 224 |
How it is read
Names in the registry
- “Lazertinib”, 12 entries
- “Lazertinib 240 mg/160 mg”, 1 entry
- “YH25448”, 1 entry
- “Lazertinib(G001)”, 1 entry
- “Lazertinib(G002)”, 1 entry
Codes read as this program: G001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Osteoarthritis, Knee, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.